We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities
Read MoreHide Full Article
Key Takeaways
PacBio introduced CiFi to generate haplotype-resolved genome assemblies from limited sample material.
CiFi integrates 3C with PACB's HiFi sequencing to reduce costs and simplify complex genome projects.
PacBio expects CiFi to unlock new use cases and enhance HiFi systems without requiring new hardware.
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, announced a new community-developed method, CiFi, yesterday. It enables chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run, even when sample material is limited.
It is worth mentioning that researchers in the Megan Dennis Laboratory at the University of California, Davis, showed how CiFi addresses long-standing limitations of short-read Hi-C by generating long, highly accurate reads that capture multiple chromatin interactions within a single molecule. The new method is expected to offer numerous advantages tailored to the requirements of genome biology, biodiversity studies and functional genomics.
The latest announcement is expected to significantly boost PacBio’s sequencing solutions business and strengthen its foothold in the niche space.
Trend in PACB Stock Following the News
Following the announcement, shares of the company lost nearly 4.2% till yesterday’s close.
Historically, the company has gained a top-line boost from its various product innovations and launches. Although the latest announcement is likely to be beneficial for PACB’s top-line growth in the future, the stock declined overall.
PacBio currently has a market capitalization of $615.9 million. It has a current ratio of 6.2 compared with the industry’s 2.3. In the last reported quarter, PACB delivered an earnings surprise of 25%.
Significance of PACB’s Latest Announcement
Per PacBio, CiFi delivers multi-contact reads and longer fragments by integrating chromatin conformation capture (3C) with its HiFi long-read sequencing. These fragments significantly increase the information content of proximity ligation experiments in a single Revio sequencing run.
PacBio also states that CiFi, when paired with Revio SPRQ chemistry, will likely be able to generate reference-quality assemblies using fewer cells, fewer libraries and fewer sequencing runs. This is expected to lower barriers for genome projects that have been limited by cost, complexity or sample availability.
Management believes that CiFi will likely expand PACB’s multiomics capabilities, increasing the capabilities of the HiFi sequencing systems without new hardware and unlock new customer use cases.
Industry Prospects in Favor of PacBio
Per a report by Grand View Research, the global sequencing market was estimated at $15,540.0 million in 2023 and is anticipated to reach $62,478.8 million by 2030 at a CAGR of 22.2%. Factors like the growing demand for gene therapy and a significant increase in demand for consumer genomics in recent years are likely to drive the market.
Given the market potential, the latest product availability is expected to provide a significant boost to PacBio’s business.
PACB’s Notable Developments
In November 2025, PacBio announced its third-quarter 2025 results, wherein it unveiled new SPRQ-Nx sequencing chemistry and consumables, which are expected to reduce sequencing costs by up to 40%. During the quarter, PACB launched an expanded PureTarget portfolio of long-read HiFi assays covering difficult-to-sequence genes in carrier screening, supporting throughput for up to 100,000 samples per Revio system per year.
The same month, PacBio announced that, through its partnership with Berry Genomics, the Sequel II CNDx system had received Class III Medical Device Registration approval from the National Medical Products Administration in China.
PacBio’s Share Price Performance
Shares of the company have lost 1% in the past year against the industry’s 4% rise and the S&P 500’s gain of 21.2%.
Image Source: Zacks Investment Research
PACB’s Zacks Rank & Other Key Picks
Currently, PacBio carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 3.4% against the industry’s 2.2% decline in the past year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.9%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.4%.
Cardinal Health has rallied 67.2% compared with the industry’s 11.8% growth in the past year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.1%.
IDEXX’s shares have gained 70.5% compared with the industry’s 4% growth in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities
Key Takeaways
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, announced a new community-developed method, CiFi, yesterday. It enables chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run, even when sample material is limited.
It is worth mentioning that researchers in the Megan Dennis Laboratory at the University of California, Davis, showed how CiFi addresses long-standing limitations of short-read Hi-C by generating long, highly accurate reads that capture multiple chromatin interactions within a single molecule. The new method is expected to offer numerous advantages tailored to the requirements of genome biology, biodiversity studies and functional genomics.
The latest announcement is expected to significantly boost PacBio’s sequencing solutions business and strengthen its foothold in the niche space.
Trend in PACB Stock Following the News
Following the announcement, shares of the company lost nearly 4.2% till yesterday’s close.
Historically, the company has gained a top-line boost from its various product innovations and launches. Although the latest announcement is likely to be beneficial for PACB’s top-line growth in the future, the stock declined overall.
PacBio currently has a market capitalization of $615.9 million. It has a current ratio of 6.2 compared with the industry’s 2.3. In the last reported quarter, PACB delivered an earnings surprise of 25%.
Significance of PACB’s Latest Announcement
Per PacBio, CiFi delivers multi-contact reads and longer fragments by integrating chromatin conformation capture (3C) with its HiFi long-read sequencing. These fragments significantly increase the information content of proximity ligation experiments in a single Revio sequencing run.
PacBio also states that CiFi, when paired with Revio SPRQ chemistry, will likely be able to generate reference-quality assemblies using fewer cells, fewer libraries and fewer sequencing runs. This is expected to lower barriers for genome projects that have been limited by cost, complexity or sample availability.
Management believes that CiFi will likely expand PACB’s multiomics capabilities, increasing the capabilities of the HiFi sequencing systems without new hardware and unlock new customer use cases.
Industry Prospects in Favor of PacBio
Per a report by Grand View Research, the global sequencing market was estimated at $15,540.0 million in 2023 and is anticipated to reach $62,478.8 million by 2030 at a CAGR of 22.2%. Factors like the growing demand for gene therapy and a significant increase in demand for consumer genomics in recent years are likely to drive the market.
Given the market potential, the latest product availability is expected to provide a significant boost to PacBio’s business.
PACB’s Notable Developments
In November 2025, PacBio announced its third-quarter 2025 results, wherein it unveiled new SPRQ-Nx sequencing chemistry and consumables, which are expected to reduce sequencing costs by up to 40%. During the quarter, PACB launched an expanded PureTarget portfolio of long-read HiFi assays covering difficult-to-sequence genes in carrier screening, supporting throughput for up to 100,000 samples per Revio system per year.
The same month, PacBio announced that, through its partnership with Berry Genomics, the Sequel II CNDx system had received Class III Medical Device Registration approval from the National Medical Products Administration in China.
PacBio’s Share Price Performance
Shares of the company have lost 1% in the past year against the industry’s 4% rise and the S&P 500’s gain of 21.2%.
Image Source: Zacks Investment Research
PACB’s Zacks Rank & Other Key Picks
Currently, PacBio carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 3.4% against the industry’s 2.2% decline in the past year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.9%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.4%.
Cardinal Health has rallied 67.2% compared with the industry’s 11.8% growth in the past year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.1%.
IDEXX’s shares have gained 70.5% compared with the industry’s 4% growth in the past year.